A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective

Kim, Dam; Kim, Hyojin; Cho, SeongHa; Park, Min‐Chan

doi:10.1111/1756-185x.13635

Public

A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective

Published in International Journal of Rheumatic Diseases • Jun 18, 2019

Authors:

Dam Kim

Hyojin Kim

SeongHa Cho

Abstract

AIM: To compare the cost-effectiveness of secukinumab vs adalimumab at 1 and 2 years of treatment in patients with ankylosing spondylitis (AS) by analyzing the cost per responder reported in randomized controlled trials (RCTs) from the Korean perspective. METHOD: A systematic literature search was p...

Subject

Secukinumab

Adalimumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!